Serum glutamate was elevated in children aged 3-10 years with autism spectrum disorders when they were compared with controls.

Clicks: 303
ID: 102494
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #60 of 170 articles by views in acta paediatrica (oslo, norway : 1992)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 170 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This study aimed to see whether measuring serum glutamate in children with autism spectrum disorder (ASD) could provide a biological marker that could allow early intervention.Serum glutamate was measured in 30 patients aged 3-10 years presenting with ASD to the Abou El Reesh Hospitals, Cairo University, Egypt and 30 matched controls without ASD in 2015. The Vineland Social Maturity Scale was applied to assess social competence, self- help skills and adaptive behaviour in both groups. The severity of autism was measured with the Childhood Autism Rating Scale test.The patients' group showed higher mean values of serum glutamate (5.888) than the control group (2.521) and the statistical difference was significant (p = 0.00021). There was no significant difference (p = 0.151) in the serum level of glutamate between patients receiving 1-2 mg of risperidone (6.519 ± 2.851) and those who were free from any medication for at least six weeks (5.157 ± 2.184).We found higher levels of serum glutamate in subjects with ASD and this might reflect altered glutamatergic neurotransmission which may aid early ASD detection. Further investigations are needed with a large number of participants to further clarify the possibility of using glutamate as a biomarker for ASD.
Reference Key
khalifa2019serumacta Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Khalifa, D;Shahin, O;Salem, D;Raafat, O;
Journal acta paediatrica (oslo, norway : 1992)
Year 2019
DOI
10.1111/apa.14477
URL
Keywords
Biomarker autism spectrum disorder excitotoxicity glutametergic neurotransmission serum glutamate

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.